1 |
Lo, H. J., J. R. Kohler, B. DiDomenico, D. Loebenberg, A. Cacciapuoti, and G. R. Fink. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90: 939-949.
DOI
ScienceOn
|
2 |
Sanchez-Martinez, C. and J. Perez-Martin. 2002. Site-specific targeting of exogenous DNA into the genome of Candida albicans using the FLP recombinase. Mol. Genet. Genomics 268: 418-424.
DOI
ScienceOn
|
3 |
Watamoto, T., L. P. Samaranayake, J. A. Jayatilake, H. Egusa, H. Yatani, and C. J. Seneviratne. 2009. Effect of filamentation and mode of growth on antifungal susceptibility of Candida albicans. Int. J. Antimicrob. Agents 34: 333-339.
DOI
ScienceOn
|
4 |
Weber, K., B. Schulz, and M. Ruhnke. 2009. Resveratrol and its antifungal activity against Candida species. Mycoses [In Press.]
|
5 |
Jung, H. J., Y. B. Seu, and D. G. Lee. 2007. Candicidal action of resveratrol isolated from grapes on human pathogenic yeast C. albicans. J. Microbiol. Biotechnol. 17: 1324-1329.
과학기술학회마을
|
6 |
Odds, F. C. 1987. Candida infections: An overview. Crit. Rev. Microbiol. 15: 1-5.
DOI
|
7 |
Kanafani, Z. A. and J. R. Perfect. 2008. Antimicrobial resistance: Resistance to antifungal agents: Mechanisms and clinical impact. Clin. Infect. Dis. 46: 120-128.
DOI
ScienceOn
|
8 |
Lee, S. K., H. J. Lee, H. Y. Min, E. J. Park, K. M. Lee, Y. H. Ahn, Y. J. Cho, and J. H. Pyee. 2005. Antibacterial and antifungal activity of pinosylvin, a constituent of pine. Fitoterapia 76: 258-260.
DOI
ScienceOn
|
9 |
Li, Y., C. Su, X. Mao, F. Cao, and J. Chen. 2007. Roles of Candida albicans Sfl1 in hyphal development. Eukaryot. Cell 6: 2112-2121.
DOI
ScienceOn
|
10 |
Ogasawara, A., N. Komaki, H. Akai, K. Hori, H. Watanabe, T. Watanabe, T. Mikami, and T. Matsumoto. 2007. Hyphal formation of Candida albicans is inhibited by salivary mucin. Biol. Pharm. Bull. 30: 284-286.
DOI
ScienceOn
|
11 |
Sudbery, P., N. Gow, and J. Berman. 2004. The distinct morphogenic states of Candida albicans. Trends Microbiol. 12: 317-324.
DOI
ScienceOn
|
12 |
Bhat, K. P. and J. M. Pezzuto. 2002. Cancer chemopreventive activity of resveratrol. Ann. NY Acad. Sci. 957: 210-229.
DOI
ScienceOn
|
13 |
Hawser, S. 1996. Comparisons of the susceptibilities of planktonic and adherent Candida albicans to antifungal agents: A modified XTT tetrazolium assay using synchronised C. albicans cells. J. Med. Vet. Mycol. 34: 149-152.
DOI
ScienceOn
|
14 |
de Repentigny, L., D. Lewandowski, and P. Jolicoeur. 2004. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin. Microbiol. Rev. 17: 729-759.
DOI
ScienceOn
|
15 |
Docherty, J. J., M. M. Fu, and M. Tsai. 2001. Resveratrol selectively inhibits Neisseria gonorrhoeae and Neisseria meningitidis. J. Antimicrob. Chemother. 47: 243-244.
DOI
ScienceOn
|
16 |
Donnelly, L. E., R. Newton, G. E. Kennedy, P. S. Fenwick, R. H. Leung, K. Ito, R. E. Russell, and P. J. Barnes. 2004. Antiinflammatory effects of resveratrol in lung epithelial cells: Molecular mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol. 287: L774-L783.
DOI
ScienceOn
|
17 |
Ignatowicz, E. and W. Baer-Dubowska. 2001. Resveratrol, a natural chemopreventive agent against degenerative diseases. Pol. J. Pharmacol. 53: 557-569.
|
18 |
Jung, H. J., I. A. Hwang, W. S. Sung, H. Kang, B. S. Kang, Y. B. Seu, and D. G. Lee. 2005. Fungicidal effect of resveratrol on human infectious fungi. Arch. Pharm. Res. 28: 557-560.
과학기술학회마을
DOI
ScienceOn
|
19 |
Abe, S., T. Satoh, Y. Tokuda, S. Tansho, and H. Yamaguchi. 1994. A rapid colorimetric assay for determination of leukocytemediated inhibition of mycelial growth of Candida albicans. Microbiol. Immunol. 38: 385-388.
DOI
|
20 |
Abe, S., Y. Sato, S. Inoue, H. Ishibashi, N. Maruyama, T. Takizawa, H. Oshima, and H. Yamaguchi. 2003. Anti-Candida albicans activity of essential oils including lemongrass (Cymbopogon citratus) oil and its component, citral. Nippon Ishinkin Gakkai Zasshi 44: 285-291.
DOI
ScienceOn
|
21 |
Baur, J. A. and D. A. Sinclair. 2006. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 5: 493-506.
DOI
ScienceOn
|